During Merck & Co. Inc. Merck & Co. Inc.’s Nov. 10 analyst meeting, Roger Pomerantz, it head of infectious diseases, talked about the progress of Merck’s hepatitis C franchise.
Pomerantz, who joined Merck in 2010 from Johnson & Johnson’s Tibotec, has been named the new head of Merck’s infectious diseases unit and is set to become the head of Merck’s head of worldwide licensing and